Evidence map›Paper›PMID 31917372›Full record

ArticleJMIR research protocols2020

Early Signs Monitoring to Prevent Relapse in Psychosis and Promote Well-Being, Engagement, and Recovery: Protocol for a Feasibility Cluster Randomized Controlled Trial Harnessing Mobile Phone Technology Blended With Peer Support.

Andrew Gumley, Simon Bradstreet, John Ainsworth, Stephanie Allan, Mario Alvarez-Jimenez, Louise Beattie, Imogen Bell, Max Birchwood, Andrew Briggs, Sandra Bucci and 28 more

Open access · goldAbstract read
In one paragraph

Article in JMIR research protocols, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Article
  13. The growing field of digital psychiatry: current evidence and the future of apps, social media, chatbots, and virtual reality.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2021
    Article
  14. Ensuring patient and public involvement in the transition to AI-assisted mental health care: A systematic scoping review and agenda for design justice.Health expectations : an international journal of public participation in health care and health policy · 2021
    Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors at 16 institutions in 2 countries.

Andrew GumleyGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-8888-938X
Simon BradstreetGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-0339-1882
John AinsworthDivision of Informatics, Imaging, and Data Sciences, School of Health Sciences, University of Manchester, Manchester, United Kingdom.ORCID https://orcid.org/0000-0002-2187-9195
Stephanie AllanGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-1016-0708
Mario Alvarez-JimenezOrygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia.ORCID https://orcid.org/0000-0002-3535-9086
Louise BeattieGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-6281-8305
Imogen BellOrygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia.ORCID https://orcid.org/0000-0001-7567-0517
Max BirchwoodDivision of Mental Health and Wellbeing, University of Warwick, Warwick, United Kingdom.ORCID https://orcid.org/0000-0002-7476-0171
Andrew BriggsLondon School of Hygiene and Tropical Medicine, London, United Kingdom.ORCID https://orcid.org/0000-0002-0777-1997
Sandra BucciDivision of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, United Kingdom.ORCID https://orcid.org/0000-0002-6197-5333
Emily CastagniniLa Trobe University, Melbourne, Australia.ORCID https://orcid.org/0000-0002-7715-2462
Andrea ClarkGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-4558-3049
Sue M CottonOrygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia.ORCID https://orcid.org/0000-0002-9386-8348
Lidia EngelDeakin University, Melbourne, Australia.ORCID https://orcid.org/0000-0002-7959-3149
Paul FrenchManchester Metropolitan University, Manchester, United Kingdom.ORCID https://orcid.org/0000-0003-4300-387X
Reeva LedermanSchool of Computing and Information Systems, Melbourne School of Engineering, University of Melbourne, Melbourne, Australia.ORCID https://orcid.org/0000-0003-4005-329X
Shon LewisDivision of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, United Kingdom.ORCID https://orcid.org/0000-0003-1861-4652
Matthew MachinDivision of Informatics, Imaging, and Data Sciences, School of Health Sciences, University of Manchester, Manchester, United Kingdom.ORCID https://orcid.org/0000-0001-6600-9508
Graeme MacLennanThe Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, United Kingdom.ORCID https://orcid.org/0000-0002-1039-5646
Claire MatrunolaGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-3617-7911
Hamish McLeodGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-4225-1815
Nicola McMeekinGlasgow Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0003-2918-8820
Cathrine MihalopoulosDeakin University, Melbourne, Australia.ORCID https://orcid.org/0000-0002-7127-9462
Emma MortonAustralian Catholic University, Melbourne, Australia.ORCID https://orcid.org/0000-0001-6179-1983
John NorrieUsher Institute, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0000-0001-9823-9252
Frank ReillyScottish Recovery Network, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-3742-6668
Matthias SchwannauerSchool of Health and Social Sciences, University of Edinburgh, Edinburgh, United Kingdom.ORCID https://orcid.org/0000-0002-4683-2596
Swaran P SinghDivision of Mental Health and Wellbeing, University of Warwick, Warwick, United Kingdom.ORCID https://orcid.org/0000-0003-3454-2089
Lesley SmithScottish Recovery Network, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0001-6382-3192
Suresh SundramMonash University, Melbourne, Australia.ORCID https://orcid.org/0000-0002-9674-0227
David ThomsonGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-1657-9462
Andrew ThompsonOrygen, The National Centre of Excellence in Youth Mental Health, Melbourne, Australia.ORCID https://orcid.org/0000-0002-0567-6013
Helen WhitehillGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-0864-7322
Alison Wilson-KayGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0002-0879-2861
Christopher WilliamsGlasgow Institute of Health and Wellbeing, Glasgow Mental Health Research Facility, University of Glasgow, Glasgow, United Kingdom.ORCID https://orcid.org/0000-0001-5387-2863
Alison YungDivision of Psychology and Mental Health, School of Health Sciences, University of Manchester, Manchester, United Kingdom.ORCID https://orcid.org/0000-0002-0401-9791
John FarhallLa Trobe University, Melbourne, Australia.ORCID https://orcid.org/0000-0003-2439-2830
John GleesonAustralian Catholic University, Melbourne, Australia.ORCID https://orcid.org/0000-0001-7969-492X
University of Glasgow · GBNHS Greater Glasgow and Clyde · GBManchester Academic Health Science Centre · GBUniversity of Warwick · GBAustralian Catholic University · AUDeakin University · AUGreater Manchester Mental Health NHS Foundation Trust · GBLa Trobe University · AUNational Health Service Scotland · GBOrygen Youth Health · AUThe University of Melbourne · AUUniversity of Edinburgh · GBEastern Health · AULondon School of Hygiene & Tropical Medicine · GBManchester Metropolitan University · GBUniversity of Aberdeen · GB

Funding

Chief Scientist Office HSRU1Department of Health HTA/13/154/04
6 · The paper itself

Abstract

backgroundRelapse in schizophrenia is a major cause of distress and disability and is predicted by changes in symptoms such as anxiety, depression, and suspiciousness (early warning signs [EWSs]). These can be used as the basis for timely interventions to prevent relapse. However, there is considerable uncertainty regarding the implementation of EWS interventions.

objectiveThis study was designed to establish the feasibility of conducting a definitive cluster randomized controlled trial comparing Early signs Monitoring to Prevent relapse in psychosis and prOmote Well-being, Engagement, and Recovery (EMPOWER) against treatment as usual (TAU). Our primary outcomes are establishing parameters of feasibility, acceptability, usability, safety, and outcome signals of a digital health intervention as an adjunct to usual care that is deliverable in the UK National Health Service and Australian community mental health service (CMHS) settings. We will assess the feasibility of candidate primary outcomes, candidate secondary outcomes, and candidate mechanisms for a definitive trial.

methodsWe will randomize CMHSs to EMPOWER or TAU. We aim to recruit up to 120 service user participants from 8 CMHSs and follow them for 12 months. Eligible service users will (1) be aged 16 years and above, (2) be in contact with local CMHSs, (3) have either been admitted to a psychiatric inpatient service or received crisis intervention at least once in the previous 2 years for a relapse, and (4) have an International Classification of Diseases-10 diagnosis of a schizophrenia-related disorder. Service users will also be invited to nominate a carer to participate. We will identify the feasibility of the main trial in terms of recruitment and retention to the study and the acceptability, usability, safety, and outcome signals of the EMPOWER intervention. EMPOWER is a mobile phone app that enables the monitoring of well-being and possible EWSs of relapse on a daily basis. An algorithm calculates changes in well-being based on participants' own baseline to enable tailoring of well-being messaging and clinical triage of possible EWSs. Use of the app is blended with ongoing peer support.

resultsRecruitment to the trial began September 2018, and follow-up of participants was completed in July 2019. Data collection is continuing. The database was locked in July 2019, followed by analysis and disclosing of group allocation.

conclusionsThe knowledge gained from the study will inform the design of a definitive trial including finalizing the delivery of our digital health intervention, sample size estimation, methods to ensure successful identification, consent, randomization, and follow-up of participants, and the primary and secondary outcomes. The trial will also inform the final health economic model to be applied in the main trial.

trial registrationInternational Standard Randomized Controlled Trial Number (ISRCTN): 99559262; http://isrctn.com/ISRCTN99559262. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/15058.

Indexed as

mHealthpsychosisrandomized controlled trialrelapseschizophrenia

Identifiers

PMID31917372
PMCPMC6996736
OpenAlexW2979699292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.